BrightView XCT is a gamma camera for Single Photon Emission Computed Tomography (SPECT) and integ...
FDA Device Recall #Z-0203-2015 — Class II — October 23, 2013
Recall Summary
| Recall Number | Z-0203-2015 |
| Classification | Class II — Moderate risk |
| Date Initiated | October 23, 2013 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Philips Medical Systems, Inc. |
| Location | Andover, MA |
| Product Type | Devices |
| Quantity | 344 units worldwide, with approximately 114 units in the United States. |
Product Description
BrightView XCT is a gamma camera for Single Photon Emission Computed Tomography (SPECT) and integrates with an attenuation device consisting of flat panel x-ray imaging components.
Reason for Recall
It was discovered the CT portion of the scan was interrupted ( stopping the CT exposure at the time of interruption) and did not complete successfully.
Distribution Pattern
Worldwide Distribution - USA (nationwide) including Puerto Rico and the states of AZ, CA, CO, DC, DE, FL, GA, IL, MA, MD, MN, MO, MS, MT, NC, NJ, NY, OH, OK, OR, PA, TX, VT, WA and WI., and the countries of Algeria, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Gabon, Germany, Greece, India, Indonesia, Ireland, Israel, Italy, Japan, Lebanon, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Poland, Portugal, Russia, Saudi Arabia, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, United Arab Emirates, United Kingdom and Viet Nam.
Lot / Code Information
Brightview XCT
Other Recalls from Philips Medical Systems, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-1643-2015 | Class II | Pinnacle3 Software Version 10.0, Model 4598002... | Apr 23, 2015 |
| Z-1555-2015 | Class II | Philips Healthcare DuraDiagnost X- Ray | Feb 9, 2015 |
| Z-1554-2015 | Class II | Philips Healthcare DigitalDiagnost System X-Ray | Feb 9, 2015 |
| Z-0348-2016 | Class II | Philips Healthcare INTEGRIS cardio system Mod... | Feb 3, 2015 |
| Z-0350-2016 | Class II | Philips Healthcare INTEGRIS H5000F/Allura 9F ... | Feb 3, 2015 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.